Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

Launched by HEIKE E DALDRUP-LINK · Mar 1, 2012

Keywords

ClinConnect Summary

This clinical trial is studying a new way to take pictures of the body called whole body magnetic resonance (MR) imaging, which aims to help doctors see how far cancer has spread in children with solid tumors. The trial is looking for children who have been diagnosed with certain types of tumors, like malignant lymphoma or malignant sarcoma, and who are scheduled to undergo specific imaging tests. The goal is to find out if this new imaging technique can detect cancer spread as accurately, or even better, than standard tests while using little to no radiation, which is safer for kids.

To be eligible for the study, children should be between the ages of 2 and 15 and have a diagnosed solid tumor. They should also have plans for a specific imaging test called 18F-FDG-PET or 18F-FDG-PET/CT. However, very young children who need sedation or have certain medical conditions may not be able to participate. If a child joins the study, they will undergo the new imaging tests, and their results will be compared to the traditional tests to see how well they work. Overall, this trial is an exciting step towards safer and more effective ways to monitor cancer in children.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of a solid extra-cranial tumor like malignant lymphoma or malignant sarcoma and
• • Scheduled for or completed a 18F-FDG-PET or 18F-FDG-PET/CT tumor staging procedure.
• • There will be no restrictions on prior treatment.
• • Very young children who need sedation or anesthesia will be excluded from the study.
• • In this pediatric \& adult study, the participant or parent/guardian is consented, and the patient when a minor is given an assent form and involved in the discussion as appropriate.
• Exclusion Criteria:
• • MR-incompatible metal implants,
• • need of sedation or claustrophobia.
• • Hemosiderosis/hemochromatosis (patients can still be included in 2nd branch without ferumoxytol)
• • There will be restrictions regarding use of other Investigational Agents: Pt with iron-overload will not receive Ferumoxytol
• • History of allergic reactions to similar compounds will be obtained and patients with a positive history of allergic reaction to iron compounds or other severe allergic reactions.will be excluded from the study.
• • Pregnant women and fetuses.